NextCure Inc., a biotechnology company, has released a corporate presentation outlining its recent developments and plans. The presentation highlights the company's global rights (excluding China) for Simcere Zaiming's SIMOSOS (CDH6) and notes the initiation of Phase 1 trials in China with FDA IND clearance. NextCure intends to leverage its existing infrastructure to initiate a US trial in the third quarter of 2025 and aims to combine data from China and US Phase 1 trials for a fast and definitive proof of concept. The presentation also mentions that Phase 1 readouts for LNCB74 and SIMOSOS are expected in the first half of 2026. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.